02 Dec 2021 (details coming soon)
Patient Treatment Selection & Disease Monitoring by CTC enumeration
Join our expert panelists and learn from their experience utilizing the RareCyte platform for CTC enumeration, biomarker expression and single cell sequencing. Specifically addressing how CTC detection is possible in multiple types of GI tumors such as colorectal, esophageal, cholangiocarcinoma and pancreatic cancer.
Circulating Tumor Cell Analysis: Delivering on the Promise of Liquid Biopsy
CTC analysis via liquid biopsy (blood) allows for a less-invasive method to identify cancer cells and can prove helpful in prognosis, treatment selection, patient stratification, and patient monitoring. Our two distinguished speakers, with over 50 years of combined experience in the field, will walk through these applications and supporting data.
WATCH THE WEBINAR
Resolving the Complexity of Tissue Immune Response with Orion High-Dimensional Imaging
High-dimensional imaging allows identification of immune cell sub-types for investigation of cell number, density, proximity, and activation state. The breakthrough Orion platform generates same-day whole-slide images with sub-cellular imaging resolution in a single stain, single scan workflow with customizable staining panels. This webinar describes the application of 17-plex immuno-oncology fluorescence panel and H & E images on the same tissue sections for investigation of the complexity of immune response in normal and malignant tissues.
Analytical Validation of CTC Enumeration using the RareCyte Platform and Implementation in a Global Clinical Trial
This webinar describes how the RareCyte platform for CTC analysis was validated in the Clinical Diagnostics Lab (CAP accredited CLIA Lab) at Eli Lilly. The results met the requirements of the Clinical Drug Study Team and the RareCyte platform was added to a global clinical trial for further evaluation in collaboration with a CRO. A short presentation on RareCyte CTC assays for enumeration, multi-biomarker analysis, and custom assay development capabilities follows.
WATCH THE WEBINAR
|RarePlex® Panel and Developer Assays for CTC enumeration and characterization|
|Presented by Arturo Ramirez, Ph.D., Director of Oncology R&D
This 7 minute overview of RarePlex Panel Kits and Developer technology highlights available circulating tumor cell assays from RareCyte and presents an introduction to our assay design and validation.
|Working with the RarePlex® Developer Kit|
|Presented by Edward Lo, Ph.D., Scientist, Assay Development Lead
Developer technology from RareCyte enables you to add up to two custom biomarkers to your CTC assay. This 5 minute video will walk you through each step of the Developer process and provide examples of completed assays.
|RareCyte technology presentation at Harvard Medical School|
|RareCyte technology presentation at Harvard Medical School titled “High Performance Multiplexed Imaging and Microregion Retrieval for Sequencing” presented by Leighton Howells, Vice President of Business Development, and Kyla Teplitz, Sr. Product Manager.|
|RarePlex® Assays: Design and Analytical Validation|
|Presented by Dr. Tad George, Sr. VP of Biology R&D
RarePlex Assays are sensitive, specific, and reproducible assays for CTC detection and biomarker expression. Gain insight into the principles RareCyte applies to its assay design and validation process in this 11 minute video.
|Tissue transcriptomics with CyteFinder® II Instruments|
|Presented by Jennifer Chow, PhD, Principal Scientist
This 5 minute overview of RareCyte’s spatial transcriptomics technology highlights how multiplex imaging and needle-based retrieval with the CyteFinder II platform enables discovery applications with FFPE and fresh frozen tissue samples.